Introduction
Introduction Statistics Contact Development Disclaimer Help
.-') _ .-') _
( OO ) ) ( OO ) )
.-----. ,--./ ,--,' ,--./ ,--,'
' .--./ | \ | |\ | \ | |\
| |('-. | \| | )| \| | )
/_) |OO )| . |/ | . |/
|| |`-'| | |\ | | |\ |
(_' '--'\ | | \ | | | \ |
`-----' `--' `--' `--' `--'
lite.cnn.com - on gopher - inofficial
ARTICLE VIEW:
New GLP-1 pill for weight loss may be closer to reality as drugmaker
Eli Lilly says it will file for regulatory approval
By Jen Christensen, CNN
Updated:
11:14 AM EDT, Tue August 26, 2025
Source: CNN
The latest results from a trial of a pill form popular GLP-1
medications offer enough information for the Eli Lilly to request
global regulatory approval this year, the company said Tuesday.
Lilly, which makes the injectable drugs to treat obesity and and to
treat diabetes, is among several chasing an effective pill form of such
GLP-1 receptor agonists. , the US Food and Drug Administration accepted
Novo Nordisk’s marketing application for an oral version of its
weight-loss drug Wegovy, with a decision expected toward the end of the
year.
The only semaglutide pill that’s currently available, , treats type 2
diabetes and comes with diet restrictions that are not necessary with
Lilly’s pill. To work best, Rybelsus needs to be taken on an empty
stomach with no more than 4 ounces of plain water first thing in the
morning. The patient should then wait at least 30 minutes to eat, drink
or take other medicines.
GLP-1s have been highly popular with millions of people using them for
weight loss and diabetes, but injections can have several disadvantages
compared with pills. They have to be refrigerated and are more
difficult and more expensive to make – and many people just don’t
like needles.
The late-stage trial results that Lilly announced Tuesday showed that
its GLP-1 pill, orforglipron, was safe and effective at helping people
with overweight and obesity and type 2 diabetes. The information was
shared in a news release and has not been peer-reviewed or published in
a medical journal.
On average, study participants lost an average of 22.9 pounds (10.5%
of their weight) on the highest dose of the medication (36 milligrams)
after they used orforglipron once a day for 72 weeks.
The pill also lowered A1C – a measurement of the average amount of
glucose in the blood over the previous three months – by an average
of 1.8%, Lilly said.
Glucose, or blood sugar, is the body’s main source of energy. People
who have diabetes can’t make enough insulin, a hormone that helps
keep blood sugar levels in a certain range. People with type 2 diabetes
may also have cells that are resistant to the effects of insulin.
GLP-1 drugs help control blood sugar by stimulating the pancreas to
release insulin and suppressing the release of another hormone to help
reduce feelings of hunger and make people feel full for longer.
Lilly has previously released trial results showing that the pill form
of its GLP-1 drug was safe and effective for people with overweight and
obesity; another announcement focused on results among people who had
type 2 diabetes alone. Tuesday’s announcement says the company now
has the “full clinical data package required to initiate global
regulatory submissions for orforglipron.”
In the latest trial, the pill’s side effects were similar to those
reported with injectable forms of GLP-1 drugs. The adverse events were
considered generally mild to moderate, according to the company, with
upset stomach the most commonly reported.
Dr. Dan Skovronsky, Lilly’s chief scientific officer, said in April
that his company has begun mass-producing orforglipron pills after
previous promising results.
“That way, we’ll have adequate supply to meet demand,” he said.
Lilly plans to publish the results of its late-stage trial in a
peer-reviewed journal. It’s also testing to see whether a pill might
help treat high blood pressure and sleep apnea, two conditions that
have been helped with certain injectable GLP-1s.
Some experts see a place for the pill version of these drugs as kind of
maintenance alternative that people could switch to after reaching a
target weight or blood sugar level by using the injectable versions
once a week.
<- back to index
You are viewing proxied material from codevoid.de. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.